Key Statistics for 460
|Current P/E Ratio (ttm)
Relative P/E vs.
|Earnings Per Share (CNY) (ttm)
|Est. EPS (CNY) (12/2013)
|Est. PEG Ratio
|Market Cap (M HKD)
|Shares Outstanding (M)
|30 Day Average Volume
|Dividend Indicated Gross Yield
|Cash Dividend (CNY)
|5 Year Dividend Growth
|Next Earnings Announcement
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for 460
- Net Income (M/CNY)
Sihuan Pharmaceutical Holdings Group Ltd. researches and develops cardiocerebral vascular drugs in China. The Company drugs address needs in the areas of anti-infective, metabolism, cardiovascular system, oncology and nervous system.
More Company Profile & Key Executives for 460
|Che FengshengChairman/CEO/Co-Founder||Guo WeichengDeputy Chairman/Co-Founder|
|Choi Yiau ChongCFO/Joint Secretary||Jia ZhongxinChief Operating Officer|
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.